The initial public offering (IPO) calendar for this week lists six companies with plans to enter the public market. Of the eight companies that had scheduled IPOs last week, seven succeeded, but their success was definitely mixed.

Through the week ending July 17th, IPO ETF manager Renaissance Capital reported that 112 IPOs have priced in the U.S. so far this year, down about 28% from a year ago. Total proceeds raised through June equaled $19 billion, down about 41% compared with the same period in 2014. Of the 112 IPOs that have gone off this year, 49 have come from the healthcare sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past ten years. Renaissance Capital does not include “best efforts” or blank check companies in its totals.

Last week’s largest one-day pop was posted by ProNAi Therapeutics Inc. (NASDAQ: DNAI) with a gain of 81% after pricing above its expected range. Chiasma Inc. (NASDAQ: CHMA) also priced above its range and posted a first-day pop of 58%. Last week’s sole hard-luck IPO was communications provider Ooma Inc., which dropped 16% on its first day of trading.

Of the six firms lined up to price and begin trading in the coming week we have two healthcare firms, a REIT, a pet products company, a blank check company, and a small business lending company.

The only one of last week’s scheduled IPOs that did not make it out the door was BioCardia Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases. The company plans to try again this week with the same offer: 3.9 million shares in an expected price range of $12 to $14 a share to raise $50 million at a market cap of $145.6 million. Joint bookrunners for the offering are Cantor Fitzgerald, Roth Capital, and Maxim Group LLC. Shares are listed as day-to-day and are expected to list on the Nasdaq under the ticker symbol BCDA.

ETRE REIT LLC was formed to permit public investment in individual commercial real estate properties. The company plans to offer 11.5 million shares at an IPO price of $15 to raise $172.5 million at an indicated market cap of $173 million. Joint bookrunners for the offering include Sandler O’Neill, Evercore Partners, and Nomura Securities. Co-managers include BTIG, JMP Securities, LOYAL3 Securities, RCS Capital, and SMBC Nikko. Shares are only listed to begin trading in the week of July 20th, and will trade on the Nasdaq under the ticker symbol ESSF.

Buffalo Pet Products Inc. is a U.S. pet food company that sells dog and cat food made with whole meats, fruits and vegetables, and other high-quality, natural ingredients under the BLUE brand. The company plans to offer 29.5 million shares in an expected price range of $16 to $18 to raise $502 million at an implied market cap of $3.33 billion. Joint bookrunners for the offering include J.P. Morgan, Citi, Barclays, Deutsche Bank, and Morgan Stanley. Co-managers are Wells Fargo Securities and LOYAL3 Securities. Shares are expected to price Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol BUFF.

Hennessy Capital Acquisition Corp. II is a blank check company. The company plans to sell 17.5 million units comprised of one share of common stock and one warrant to purchase one-half share of common stock at $5.75 per half-share. The IPO price is $10 per unit and the company plans to raise $175 million at the offering. Managers for the offering are UBS Investment Bank, Cantor Fitzgerald, and BMO Capital Markets. Units are scheduled to begin trading Thursday on the Nasdaq under the ticker symbol HCACU. Common stock will trade under the symbol HCAC and warrants will trade as HCACW once the units securities begin trading separately.

Live Oak Bancshares Inc. is a national online platform for small business lending. The company plans to offer 4 million shares in an expected price range of $16 to $18, raising $68 million at an implied market cap of $555 million. Joint bookrunners for the offering are Sandler O’Neill, Keefe Bruyette Woods, and Suntrust Robinson Humphrey. Shares are scheduled to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol LOB.

Neo Therapeutics Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products using its proprietary modified-release drug delivery technology platform. The company plans to offer 4 million shares in an IPO price range of $14 to $16 to raise $60 million at an implied market cap of $205.4 million. Joint bookrunners for the offering include UBS Investment Bank, BMO Capital Markets, and RBC Capital Markets. Co-manager is JMP Securities. Shares are scheduled to price Wednesday and begin trading Thursday on the Nasdaq under the ticker symbol NEOS.

ALSO READ: 7 Key DJIA Stocks Reporting Earnings This Week

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.